Business

California-based InCarda Therapeutics (formerly Pleiades Cardio-Therapeutics) has announced that it raised over $5 million with the possibility of an additional $1.5 million in a private financing round led by Morningside Venture. According to the company, it will use the proceeds for development of an inhaled therapy for paroxysmal atrial fibrillation. InCarda … [Read more...] about InCarda raises more than $5 million for development of inhaled cardiac drugs

According to Mylan, the United States Court of Appeals for the Federal Circuit has affirmed a lower court's March 2014 decision upholding the validity of four Mylan patents related to Perforomist formoterol fumarate inhalation solution and infringement of the patents by Teva. The patents (Nos. 6,667,344; 6,814,953; 7,348,362; and 7,462,645) protect Perforomist … [Read more...] about Court of Appeals upholds Mylan Perforomist patents

AstraZeneca announced that it has entered into a five-year partnership agreement with patient network PatientsLikeMe for access to patient-reported data in several treatment areas, including respiratory. PatientsLikeMe offers a program called "data for good," whose slogan is "donate your data for you, for others, for good." On its website, the company informs … [Read more...] about AstraZeneca partners with PatientsLikeMe

CDMO Molecular Profiles has announced that the company has a new name: Juniper Pharma Services. The company, whose services include formulation development and clinical trial manufacturing of dry powder inhalers, was acquired in 2013 by US-based Columbia Laboratories, now called Juniper Pharmaceuticals. In April 2014, Molecular Profiles announced that it planned to … [Read more...] about Molecular Profiles changes name to Juniper Pharma Services

Vectura has announced that it will close the former Activaero nebulizer manufacturing site in Gemünden, Germany by March 2016, transfering many of the site's operations to other Vectura facilities in Germany and the UK. Commercial production will be transferred to a contract manufacturing organization. Vectura acquired the Gemünden site when it acquired Activaero in … [Read more...] about Vectura to close former Activaero site in Gemünden

The European Patent Office has granted Evoke Pharma patent no. 2376075 for its EVK-001 intranasal metoclopramide for the treatment of diabetic gastroparesis symptoms in women, the company said. Earlier this year, Evoke announced that Phase 3 development of EVK-001 has been delayed by slower than expected enrollment in an ongoing clinical trial. Evoke President and … [Read more...] about Evoke Pharma’s intranasal metoclopramide formulations get European patent

Aptar Pharma has announced that a new budesonide DPI launched in China by Shanghai Sine Promod Pharmaceutical is the first marketed product to incorporate Aptar's new Twister device. The new 200µg dose budesonide inhaler is available in 30 capsule and 60 capsule versions for the treatment of asthma. In April 2012, Aptar Pharma announced the availability of the … [Read more...] about Shanghai Sine Promod Budesonide DPI incorporates Aptar’s Twister device

Insmed Incorporated has announced that it is offering 10 million shares of its common stock at $20.65 per share, which it expects to generate net proceeds of about $194 million. The company says that it will use the money for expenses related to Arikayce inhaled liposomal through commercialization, for further development of INS1009 inhaled treprostinil prodrug … [Read more...] about Insmed announces public stock offering to support Arikayce development

Par Specialty Pharmaceuticals (formerly called Strativa Pharmaceuticals) has launched a single use version of Nascobal cyanocobalamin nasal spray for the treatment of pernicious anemia and other vitamin B12 deficiencies, the company said. The FDA approved the single dose, once-a-week product, which is packaged in cartons of four, in June 2014. The company also … [Read more...] about Par launches Nascobal single use cyanocobalamin nasal spray

Discovery Laboratories has announced that it will switch its focus from Surfaxin lucinactant intratracheal suspension product to development of its Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants. The company said that if it is unable to find a partner for Surfaxin, it will "cease the commercialization" of … [Read more...] about Discovery Labs restructuring to focus on Aerosurf program